Responses of Adults Smoking Nondaily and Daily in the Experimental Tobacco Marketplace
Launched by BETHANY SHOREY FENNELL · May 15, 2025
Trial Information
Current as of November 12, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This study is exploring how proposed tobacco product rules might affect how adults who smoke decide what to buy. In a realistic online “marketplace,” participants will shop for nicotine/tobacco products under different regulatory scenarios (for example, changes to nicotine levels or flavor rules). They’ll complete purchasing tasks to simulate buying a week’s worth of products, and researchers will look at how much people buy, what substitutions they make, and how price affects choices under each scenario.
Who can join? Adults 18 and older who smoke cigarettes at least 4 days per month, including both daily and nondaily smokers, and who do not plan to quit nicotine/tobacco soon. They must be able to read English and be healthy enough to participate. The study involves an online consent and surveys, plus the simulated online shopping task. Participants will be randomly assigned to different regulatory scenarios. There are no drugs or devices involved, and the study is currently enrolling, with about 800 participants planned. Results are not yet available.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • At least 18 years old
- • Consume cigarettes 4-30 days per month
- • Have no plans to quit nicotine/tobacco products
- • Read and understand English
- Exclusion Criteria:
About Bethany Shorey Fennell
Bethany Shorey Fennell is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes. With a focus on innovative therapies and evidence-based practices, Fennell oversees a diverse portfolio of clinical studies across various therapeutic areas. Leveraging extensive expertise in trial management and regulatory compliance, she ensures that each study adheres to the highest ethical standards while fostering collaboration among researchers, healthcare professionals, and stakeholders. Her leadership is characterized by a commitment to transparency, integrity, and the pursuit of scientific excellence, aiming to bridge the gap between research and real-world application.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lexington, Kentucky, United States
Patients applied
Trial Officials
Bethany Shorey Fennell, PhD
Principal Investigator
University of Kentucky
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported